X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with bis-(aza-18-crown-6)-poloxamer, and adjuvant AlPO4. It is being evaluated for the treatment of SARS-CoV-2 XBB.1.5 variant.
Lead Product(s): IMNN-101
Therapeutic Area: Infections and Infectious Diseases Product Name: IMNN-101
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with bis-(aza-18-crown-6)-poloxamer, and adjuvant AlPO4. It is being evaluated for the treatment of SARS-CoV-2 XBB.1.5 variant.
Lead Product(s): IMNN-101
Therapeutic Area: Infections and Infectious Diseases Product Name: IMNN-101
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with bis-(aza-18-crown-6)-poloxamer, and adjuvant AlPO4. It is being evaluated for the treatment of SARS-CoV-2 XBB.1.5 variant.
Lead Product(s): IMNN-101
Therapeutic Area: Infections and Infectious Diseases Product Name: IMNN-101
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
GEN-1 (IMNN-001) is a DNA-based interleukin-12 (IL-12) immunotherapy, which is being evaluated in combination with bevacizumab for the treatement of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: GEN-1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that is investigated in combination with bevacizumab for the treatment of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that is investigated for the treatment of epithelial ovarian cancer.
Lead Product(s): IMNN-001,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The agreement aims to evaluate the immunogenicity and efficacy of two IMUNON DNA-based Lassa virus vaccine candidates. NIAID will assess the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models.
Lead Product(s): DNA-based Lassa Virus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2023
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein which is one of the most active cytokines for the induction of potent anticancer immunity.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Break Through Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Under the agreement, IMUNON’s PLACCINE Vaccine Platform will be utilize to research and develop new vaccine formulations for the development of vaccines for infectious diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: The Wistar Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2023
Details:
PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions.The plasmid vector is designed to express multiple pathogen antigens along with the option to include a potent immune modifier.
Lead Product(s): COVID-19 DNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Placcine
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
